scholarly journals High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice

Dermatology ◽  
2010 ◽  
Vol 220 (2) ◽  
pp. 128-137 ◽  
Author(s):  
Jean-Hilaire Saurat ◽  
Annie Guérin ◽  
Andrew P. Yu ◽  
Dominick Latremouille-Viau ◽  
Eric Q. Wu ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Real World ◽  
Economic Outcomes ◽  
Potential Drug ◽  
High Prevalence

scholarly journals The Prevalence of Selected Potential Drug-Drug Interactions of Analgesic Drugs and Possible Methods of Preventing Them: Lessons Learned From the Analysis of the Real-World National Database of 38 Million Citizens of Poland

2021 ◽  
Vol 11 ◽  
Author(s):  
Przemysław Kardas ◽  
Filip Urbański ◽  
Aneta Lichwierowicz ◽  
Ewa Chudzyńska ◽  
Marcin Czech ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Real World ◽  
Selective Serotonin Reuptake Inhibitors ◽  
National Database ◽  
Public Healthcare ◽  
Polish Population ◽  
Potential Drug ◽  
Analgesic Drugs ◽  
The Real ◽  
High Prevalence

Introduction: Drug-drug interactions may lead to poor health outcomes, as well as increased costs and utilization of healthcare services. Unfortunately, real-world data continuously prove high prevalence of potential drug-drug interactions (pDDIs) worldwide. Among identified drivers, ageing, multimorbidity and polypharmacy play a very important role. With these factors being widespread, the need for implementation of strategies minimizing the burden of pDDIs becomes an urgency. This, however, requires a better understanding of the prevalence of pDDIs and the underlying causative factors.Aim of study: To assess the real-world prevalence of pDDIs and its characteristics in the general population of Poland, using analgesic drugs as a model, and to find out whether pDDIs are caused by prescribing coming from the very same prescribers (co-prescribing).Methods: A retrospective analysis of the 2018 dispensation data of the National Health Fund (NHF) - the only Polish public healthcare payer organization with nationwide coverage. We searched for selected pDDIs of non-steroidal anti-inflammatory drugs (NSAIDs) with antihypertensives, other NSAIDs (double use), oral glucocorticoids, oral anticoagulants, selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and antiplatelet drugs; as well as opioides with SSRIs, SNRIs, gabapentinoids, and benzodiazepines. A pDDI was deemed present if two drugs standing in a possible conflict were dispensed within the same calendar month.Results: Out of 38.4 million citizens of Poland, 23.3 million were dispensed prescribed drugs reimbursed by NHF in 2018. In this cohort, we have identified 2,485,787 cases of analgesic drug pDDIs, corresponding with 6.47% of the Polish population. Out of these, the most prevalent pDDI was caused by “NSAIDs + antihypertensives” (1,583,575 cases, i.e., 4.12% of the Polish population), followed by “NSAIDs + NSAIDs” (538,640, 1.40%) and “NSAIDs + glucocorticoids” (213,504, 0.56%). The most persistent pDDIs among those studied were caused by “Opioids + Gabapentinoids” (2.19, 95%CI: 2.16–2.22 months). On average, 76.63% of all cases of pDDIs were caused by drugs prescribed by the very same prescribers.Conclusion: Based on high-quality, nationwide data, we have found a high prevalence of analgesic drugs-related pDDIs in Poland. Over ¾ of the identified pDDIs were caused by co-prescribing, i.e., prescriptions issued by the same prescribers. The significance of the problem, illustrated with our findings on analgesic drugs-related pDDIs in Poland, deserves much more scientific and policymaker attention.

Prevalence of potential drug-drug interactions among nonmetastatic castration-resistant prostate cancer patients treated with apalutamide and enzalutamide.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18690-e18690
Author(s):  
Sreevalsa Appukkuttan ◽  
Chunmay Fu ◽  
Yuxian Du ◽  
Ashley Cha ◽  
Jacqueline Parkin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Interactions ◽  
Real World ◽  
Potential Drug ◽  
Adult Males ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
High Prevalence ◽  
Study Population ◽  
Concomitant Medications

e18690 Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are often treated with concurrent medications for the management of comorbid conditions. This increases the risk of drug interactions which may lead to compromised efficacy and safety of nmCRPC therapies. This study aimed to characterize potential drug-drug interactions (pDDIs) with the novel anti-androgen (AA) agents enzalutamide (Enza) and apalutamide (Apa) in a real-world nmCRPC population. Methods: We analyzed Optum Clinformatics Data Mart, a large claims database from January 1, 2017, through March 31, 2020. The study population included adult males with prostate cancer, evidence of castration, >1 pharmacy claim for Apa or Enza (index date defined as drug initiation), and without codes for metastases. Darolutamide, a more recently approved AA, was not included due to lack of data. Concomitant medications were defined as therapy with at least 1 day overlap with Apa and Enza. The top concomitant medications covering 99% of Apa and Enza population were assessed for pDDI using Micromedex, Lexicomp, and Drugs.com compendia. Results: We identified 149 Apa and 319 Enza patients with mean age 77 years across groups. The study population was primarily white (56.3% Apa; 56.7% Enza) and had Medicare insurance (81.0% Apa; 82.2% Enza). Mean Charlson comorbidity index scores were similar for each group (Apa: 2.3 [SD: 4.1]; Enza: 2.4 [SD: 2.4]). Polypharmacy was common in both groups, with the majority taking ≥5 medications (Apa: 79.8%; Enza: 75.9%). Of the co-medications included in this analysis, Micromedex, Lexicomp and Drugs.com flagged 12, 38 and 53 pDDIs for Apa, and 7, 35 and 49 pDDIs for Enza, respectively. A pDDI was identified for 35% Apa and 21% Enza patients using Micromedex and >80% of Apa and Enza patients using other compendia. The pDDIs by severity and risk rating as defined by the respective compendia are shown in Table. Specifically, 4 interactions for Apa and 1 for Enza were rated X (i.e., avoid combination). Conclusions: This study finds a high prevalence of pDDIs among Apa and Enza patients signifying the need for strict monitoring while initiating these therapies. Given the high prevalence of polypharmacy and comorbidities among nmCRPC, these patients may benefit from drugs with lower interaction potential. Future real-world analyses should be conducted to characterize the clinical and economic impact of these pDDIs as well as to assess pDDI for darolutamide. [Table: see text]

scholarly journals Real‐world prevalence and consequences of potential drug‐drug interactions in the first‐wave COVID‐19 treatments

2020 ◽  
Author(s):  
Noemí Martínez‐López‐de‐Castro ◽  
Marisol Samartín‐Ucha ◽  
Adolfo Paradela‐Carreiro ◽  
Antonio Pérez‐Landeiro ◽  
María Teresa Inaraja‐Bobo ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Real World ◽  
Potential Drug

scholarly journals Potential drug interactions in adults living in Manaus: a real-world comparison of two databases, 2019

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Taís Freire Galvão ◽  
Tayanny Margarida Menezes Almeida Biase ◽  
Giulia Sartori Bruniéri ◽  
Marcus Tolentino Silva
Keyword(s):  
Drug Interactions ◽  
Real World ◽  
Potential Drug

scholarly journals STUDY OF DRUG-DRUG INTERACTION IN THE INPATIENTS OF A TERTIARY CARE HOSPITAL AT CALICUT

2018 ◽  
Vol 11 (9) ◽  
pp. 162
Author(s):  
Greeshma K George ◽  
Siraj Sundaran ◽  
Ashar Ali Cp ◽  
Mubeena Km ◽  
Thansiya Ph ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Health Care Professionals ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Close Monitoring ◽  
Care Hospital ◽  
Potential Drug ◽  
High Prevalence ◽  
Medication Chart ◽  
Pharmacokinetic Drug

Objective: The study was conducted to monitor the potential drug-drug interactions in the prescriptions of inpatients in a tertiary care hospital based on the mechanism and severity.Methods: This prospective observational study was conducted by collecting the prescriptions containing two or more drugs. The interactions were checked using an interaction checker and were categorized into pharmacokinetic and pharmacodynamic interactions on the basis of mechanism of action and severity based on the risks or consequences of the interactions.Result: Among 150 randomly collected prescriptions, 123 (82%) prescriptions had 396 drug-drug interactions. The pharmacodynamic drug interactions (77.27%) were more common when compared to pharmacokinetic drug interactions (22.73%). There was high prevalence of drug-drug interactions among the patients above the age of 60 years (56.09%). The moderate drug-drug interactions (81.81%) were found to be more when compared to the major (10.61%) and minor (7.58%) interactions. The neurology department prescriptions were observed to have more number of drug-drug interactions (26.01%).Conclusion: A systematic approach and close monitoring of the medication chart is necessary to identify the potential drug-drug interactions. The clinicians and other health-care professionals at the study site require an awareness program in regard to identification and management of drug-drug interactions. Clinical pharmacist can play an important role in the monitoring and management of drug-drug interactions.

scholarly journals Statin drug-drug interactions in a Romanian community pharmacy

2016 ◽  
Vol 89 (2) ◽  
pp. 273-278 ◽  
Author(s):  
Raluca Badiu ◽  
Camelia Bucsa ◽  
Cristina Mogosan ◽  
Dan Dumitrascu
Keyword(s):  
Drug Interaction ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Community Pharmacy ◽  
Safety Profile ◽  
Potential Drug ◽  
Online Program ◽  
High Prevalence ◽  
Statin Drug

Background and aim. Statins are frequently prescribed for patients with dyslipidemia and have a well-established safety profile. However, when associated with interacting dugs, the risk of adverse effects, especially muscular toxicity, is increased.The objective of this study was to identify, characterize and quantify the prevalence of the potential drug-drug interactions (pDDIs) of statins in reimbursed prescriptions from a community pharmacy in Bucharest.Methods. We analyzed the reimbursed prescriptions including statins collected during one month in a community pharmacy. The online program Medscape Drug Interaction Checker was used for checking the drug interactions and their classification based on severity: Serious – Use alternative, Significant – Monitor closely and Minor.Results. 132 prescriptions pertaining to 125 patients were included in the analysis. Our study showed that 25% of the patients who were prescribed statins were exposed to pDDIs: 37 Serious and Significant interactions in 31 of the statins prescriptions. The statins involved were atorvastatin, simvastatin and rosuvastatin.Conclusions. Statin pDDIs have a high prevalence and patients should be monitored closely in order to prevent the development of adverse effects that result from statin interactions.

Sign in / Sign up

Export Citation Format

Share Document